Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients (Hoosier Cancer Research Network GI14-198)

Summary

The purpose of this phase II trial is to evaluate the efficacy and safety of FOLFIRINOX plus ramucirumab (Arm A) vs. FOLFIRINOX plus placebo (Arm B) patients with advanced pancreatic cancer, not amenable to curative treatment.

For more information on this trial, please go to https://hoosiercancer.org/clinical-trials/trial/gi14-198/.

General Information

NCT#: NCT02581215
Study ID: HCRN GI14-198
Trial Phase: Phase II

Trial Sponsor: Eli Lilly, Hoosier Cancer Research Network
Therapies Used in This Trial: Fluorouracil, Oxaliplatin, Irinotecan, Leucovorin, FOLFIRINOX, Ramucirumab

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search